hongo hericium

Hericium Mushroom (Hericium erinaceus): A Comprehensive Reference

1. Identity and Taxonomy

Scientific Nomenclature and Classification

Hericium erinaceus, commonly known as lion's mane mushroom, belongs to the tooth fungus family Hericiaceae and stands out dramatically from typical cap-and-stem mushrooms. Both the Latin genus name Hericium and the species name erinaceus mean "hedgehog" in Latin. The genus name Hericium is derived from hericius, meaning "hedgehog," alluding to the cascading spines that resemble the quills of a hedgehog. Similarly, the specific epithet erinaceus is the Latin adjective form of Erinaceus, the genus name for hedgehogs in Europe and the Middle East, further emphasizing the hedgehog-like texture of its fruiting body.

The full accepted scientific name is Hericium erinaceus (Bull.) Pers. Two mycologists were instrumental in its formal description: the Frenchman J. B. F. Bulliard, who gave it the name Hydnum erinaceus, while its current name was assigned by Ch. H. Persoon in 1797. The genus Hericium, within the family Hericiaceae, has been used for both food and traditional medicine for over 2,000 years in East Asian countries such as China, India, Japan, and Korea.

Common Names

The mushroom is known in Japan as yamabushitake (山伏茸) in reference to the yamabushi or mountain ascetics of the syncretistic religion known as Shugendo; in Chinese it is known as hóutóugū (猴头菇) meaning "monkey-head mushroom"; in Korea as noru gungdeng-i beoseot meaning "deer butt mushroom"; and in Europe and the United States as lion's mane.

Morphology and Habitat

The fungus derives its common name from its remarkable appearance, featuring cascading white spines that can reach 1–5 centimeters in length, creating a distinctive mane-like texture that resembles flowing hair. The mushroom grows as a single, globular to semi-spherical fruiting body ranging from 5–40 centimeters in diameter. The mature state of the fruiting body is easily discernible, with its basidiosome consisting of long branchless dangling spines that change in color from white to yellow and, eventually with aging, to brown.

This fungus is saprotrophic and weakly parasitic, primarily found growing on hardwood trees like oak, walnut, and beech, particularly on aging or injured wood in temperate forests across Asia, Europe, and North America. In many parts of Europe, intact populations are under threat due to deforestation and are considered rare or protected; in the UK, for instance, it enjoys legal protection under the Wildlife and Countryside Act.

Macronutrient Composition

H. erinaceus fruiting bodies contain 57% carbohydrates (8% as dietary fiber), 4% fat, and 22% protein.

Common Forms and Preparations

Supplement products typically contain processed material derived from the fruiting body or, sometimes, mycelium cultivated on grain substrates. Variability in commercial preparations arises from the source of raw material, extraction methods, and extract constituents. For example, extracts derived from the fruiting body, as regulated by the EU Novel Foods Catalogue, differ from those utilizing both fruiting body and mycelium, and research shows distinct bioactive profiles between the fruiting body and mycelium. The use of solvents such as ethanol, methanol, or water significantly impacts bioactive yield. Commercial forms include dried powder, capsules, tablets, tinctures, and hot-water or dual-solvent extracts.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

In traditional Chinese medicine, the mushroom is known as houtougu or "monkey head mushroom" and was prescribed to fortify the spleen, nourish the gut, and address conditions such as chronic gastritis and gastric ulcers by promoting the flow of qi and balancing internal energies. It is listed as one of the "Four Famous Cuisines" of China, together with bear's paws, trepang, and shark's fin, and has been used for a long time in traditional medicine. In traditional Chinese contexts, the mushroom has been part of the materia medica, referenced in historical texts for various applications, often prepared as a tea or in soups.

Traditional Japanese Use (Kampo Medicine)

In Japanese kampo medicine, the mushroom is referred to as yamabushitake and was employed historically to support gastrointestinal health, including the treatment of stomach ulcers, while also aiding vitality and nervous system function to combat weakness and insomnia. Buddhist monks in Japan — the yamabushi, hence the name yamabushitake — were known to incorporate it, potentially valuing its unique properties within their practices.

Other Traditional Contexts

Beyond East Asia, indigenous North American communities incorporated Hericium erinaceus into remedies, applying it topically or as a preventive measure against bleeding from wounds, leveraging its fibrous structure for wound care in traditional healing practices. Hericium erinaceus is a culinary-medicinal mushroom used traditionally in Eastern Asia to improve memory.

3. Key Constituents and Active Compounds

Overview of the Chemical Profile

102 compounds have been identified in H. erinaceus by comparison with standard databases, including flavonoids, terpenoids, phenolic acids, phenylpropanoids, steroids, organic acids, and amino acids. The mushroom as well as the fermented mycelia have been reported to produce several classes of bioactive molecules, including polysaccharides, proteins, lectins, phenols, and terpenoids.

Hericenones

Among the bioactive secondary metabolites, hericenones — a structurally unique class of geranyl-resorcinol derivatives — have emerged as particularly promising pharmacological agents. Research has identified 24 known natural hericenones and one semisynthetic derivative. Hericenones are typically found in the fruiting bodies of the mushroom. Hericenones extracted from the fruiting body can be present at concentrations ranging from less than 20 to 500 µg/g of dry weight.

Erinacines

Hericenones and erinacines represent the most significant bioactive constituents. Erinacines (A–K, P–S) are cyathin diterpenoids derived from the mycelia of the mushroom. The structures of novel diterpenoids, erinacines A, B, and C, isolated from the cultured mycelia of Hericium erinaceum, were determined by spectral data interpretation, and these compounds showed potent stimulating activity of nerve growth factor (NGF) synthesis. Erinacines found in the mycelium can reach concentrations of approximately 150 µg/g.

Polysaccharides and Beta-Glucans

Hericium erinaceus polysaccharides (HEP) have various biological activities, including anti-inflammatory, anti-oxidation, and protection of the gastrointestinal tract. HEP-1, a low-molecular-weight polysaccharide isolated from Hericium erinaceus, is composed of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→, and →3,6)-β-D-Glcp-(1→ residues.

Other Identified Compounds

Additional compounds isolated from the fruiting bodies include ergosterol peroxide, cerevisterol, betulin, oleanolic acid, ursolic acid, and hemisceramide, among others. Phenolic compounds, including gallic acid, caffeic acid, and p-coumaric acid, are also present in H. erinaceus and contribute to its strong antioxidant capacity. Ergothioneine in H. erinaceus has been detected at levels between 0.34 and 1.30 mg/g, depending on cultivation conditions.

Fruiting Body vs. Mycelium: Compound Distribution

Erinacines, found in the mycelium, potently induce the synthesis of neurotrophins — protein growth factors essential for neuronal survival and health — while hericenones from the fruiting body appear to enhance or potentiate neurotrophin-activated signaling pathways. What makes this mushroom scientifically interesting, and what makes quality evaluation genuinely complex, is that its most-studied compounds are not found in the same part of the organism.

The levels of hericenones and erinacines vary depending on the cultivation substrate and the fungal developmental stage.

4. Mechanisms of Action

Nerve Growth Factor (NGF) Stimulation

Nerve growth factor (NGF) has potent biological activities, including preventing neuronal death and promoting neurite outgrowth, and is essential to maintain and organize neurons functionally. Functional deficiency of NGF is assumed to be related to Alzheimer's disease and to play a part in the etiology of the disease process. NGF is a protein and therefore is unable to cross the blood–brain barrier; it is also easily metabolized by peptidases. Small-molecule compounds that stimulate NGF biosynthesis, such as hericenones and erinacines, are therefore of particular interest.

Since the 1990s, several in vitro studies have demonstrated the stimulatory effects on the synthesis of NGF by hericenones (C, D, E, H) and erinacines (A–F, H) extracted from H. erinaceus. To date, hericenones A–H as well as erinacines A–C, H, and I are known to stimulate synthesis of NGF in vitro, but can only do so when administered to glial cells and cannot induce NGF synthesis in neurons alone.

Erinacines A, B, C, and E have been confirmed to stimulate NGF synthesis; erinacine Z1 also increases the expression of this neurotrophin; and erinacine C has been found to also increase the expression of BDNF.

Signaling Pathways

Hericenone E increases the phosphorylation of extracellular-signal regulated kinases (ERKs) and protein kinase B (Akt), and potentiates NGF-induced neuritogenesis in PC12 cells via the MEK/ERK and PI3K/Akt pathways. Activation of these pathways, including PI3K/AKT/mTOR and MAPK/ERK, converges on transcription factors such as CREB, promoting neuronal survival, neurite outgrowth, and synaptic plasticity. Erinacine A also attenuates neurotoxicity through the upregulation of pro-survival pathways while decreasing activity of pro-apoptotic pathways.

The precise molecular mechanisms linking these small molecules to the complex orchestration of neurotrophic gene expression remain incompletely defined.

Anti-Inflammatory Mechanisms

H. erinaceus has shown various anti-inflammatory, antioxidative, and gastroprotective properties. Several polysaccharides of H. erinaceus inhibit the secretion of proinflammatory cytokines interleukin 6 (IL-6), IL-8, and IL-12 and promote the secretion of the anti-inflammatory cytokine IL-10 in cell culture systems.

BDNF Modulation

The restoration effect of H. erinaceus on BDNF is suggested to be through monoaminergic modulation and normalization, as BDNF can be influenced by monoaminergic transmitters such as serotonin, norepinephrine, and dopamine.

5. Scientific Evidence by Area of Use

5.1 Cognitive Function and Neuroprotection

Mild Cognitive Impairment — Key RCT

A double-blind, parallel-group, placebo-controlled trial was performed on 50- to 80-year-old Japanese men and women diagnosed with mild cognitive impairment (MCI) to examine the efficacy of oral administration of Hericium erinaceus. After 2 weeks of preliminary examination, 30 subjects were randomized into two 15-person groups; the Yamabushitake group took four 250 mg tablets containing 96% of Yamabushitake dry powder three times a day for 16 weeks. At weeks 8, 12, and 16, the Yamabushitake group showed significantly increased scores on the cognitive function scale compared with the placebo group. Notably, these benefits declined after the discontinuation of supplementation, suggesting a need for sustained intake to maintain cognitive enhancements. This is the most frequently cited human clinical trial, though its sample size (n=30) is a significant limitation.

Dosage Reported in Cognitive Studies

One study used 1 g three times per day of powdered lion's mane fruiting bodies (Mori et al., 2009). Another used 3.2 g of powdered lion's mane fruiting bodies per day (Saitsu et al., 2019).

Erinacine A-Enriched Mycelium Pilot Study

One randomized clinical trial investigated the effects of daily consumption of erinacine A-enriched H. erinaceus supplementation on cognitive functioning, serum biochemical markers, fecal levels of chitinase, and gut microbiota composition.

Systematic Review of Cognitive RCTs

A 2025 systematic review (PRISMA-compliant) included results from five randomized controlled trials, 15 laboratory studies, three pilot clinical trials (PCTs), one cohort study, one case report, and one computer analysis. The RCTs and PCTs assessed cognitive improvements in participants with and without dementia. Mini-Mental State Examination scores from one RCT and one PCT showed a combined weighted mean increase of 1.17 in the intervention group.

Acute Study in Healthy Young Adults

In an acute randomized, placebo-controlled, double-blinded, cross-over intervention study, the potential benefits of a single dose of H. erinaceus fruiting body extract (3 g of 10:1 extract) on cognitive performance and mood were investigated in 18 healthy participants aged 18 to 35 years. The results showed no significant effect of the H. erinaceus fruiting body extract for composite measures of global cognitive function and mood; however, participants exhibited improved performance on the pegboard test at 90 minutes following a single dose. The authors concluded that acute consumption did not demonstrate a significant overall improvement in cognitive performance and mood, and any benefits may be task- or domain-specific.

Overall Strength of Cognitive Evidence

In a large body of in vitro and in vivo preclinical studies on the central nervous system, the effects of erinacines have been correlated with a significant increase in the production of neurotrophic factors. Despite the promising outcomes of preclinical investigations, only a limited number of clinical trials have been carried out so far in different neurological conditions. The collected evidence underlines the urgent need for further, wider clinical trials to prove the safety and efficacy of H. erinaceus supplementation for neuroprotective applications in brain pathologies. Current human evidence is promising but preliminary, limited by small sample sizes and short durations.

5.2 Alzheimer's Disease and Neurodegeneration

One trial focused on the potential neuroprotective effects of H. erinaceus in patients with early-stage Alzheimer's disease. Preliminary findings indicated that regular consumption improved memory recall and reduced neuropsychiatric symptoms, likely due to its ability to stimulate NGF production and mitigate neuroinflammation. While promising, these results highlight the need for larger-scale studies with longer follow-up periods to establish definitive clinical efficacy.

In animal models, treatment of 5-month-old Alzheimer's mice for 30 days with either lion's mane mycelium or its ethanol extract reduced the number of amyloid plaques (the non-compact part, not the plaque core). This finding remains in the preclinical domain.

5.3 Anxiety, Depression, and Mood

A clinical study examined the effects of H. erinaceus on anxiety, depression, binge eating, and sleep disorders in 77 volunteers with a body mass index (BMI) ≥25 kg/m² and an average age of 53.2. The study recruited overweight or obese participants positive for one or more administered tests, including Zung's Depression Self-Assessment Scale, Zung's Anxiety Self-Assessment Scale, Symptom Checklist-90, and the Binge Eating Scale.

A clinical study on patients with depression, anxiety, and sleep disorder examined the beneficial effects of 8 weeks of oral administration of capsules containing H. erinaceus extract (1200 mg/capsule, 3 capsules/day). Results showed that pro-BDNF levels in blood serum increased after 4 weeks of administration, but there were no significant changes in serum BDNF levels; serum BDNF levels decreased after 8 weeks. The detailed underlying mechanism of the role of BDNF expression in the antidepressant effects of H. erinaceus remains unclear.

Eight weeks of oral H. erinaceus supplementation decreased depression, anxiety, and sleep disorders. Supplementation improved mood disorders of a depressive-anxious nature and the quality of nocturnal rest, and increased circulating pro-BDNF levels without any significant change in BDNF circulating levels.

Upon H. erinaceus consumption, scores on symptom-rating instruments showed significant declines, with the most remarkable improvements in symptoms such as palpitation, insensitivity, irritability, anxiety, and concentration, indicating that H. erinaceus can produce a meaningful reduction in symptoms associated with depression and anxiety through the promotion of hippocampal neurogenesis. Additionally, H. erinaceus consumption leads to modulation of serotonin receptors, which contributes to the anxiolytic and antidepressant effects observed.

Evidence in this area derives primarily from small pilot studies and open-label trials in specific populations (overweight adults, students facing examinations). The results are not validated against conventional antidepressants; furthermore, some populations studied were small, gender-specific, and their anxiety and mood disorders may have been temporary effects associated with situational stressors rather than clinically diagnosed conditions.

5.4 Gastrointestinal Health

Over the past decade, H. erinaceus has been made part of medical and health care products demonstrating beneficial effects to alleviate epigastric pain caused by chronic superficial gastritis, gastric ulcer, or atrophic gastritis.

Studies investigating gastroprotective activity of Hericium erinaceus polysaccharide (HEP) using an acetic acid-induced gastric ulcer rat model found that HEP treatment could ameliorate gastric ulcers. HEP supplementation decreased levels of interleukin-6, tumor necrosis factor-α, and malondialdehyde, and increased releases of nitric oxide, prostaglandin E2, epidermal growth factor, vascular endothelial growth factor, and basic fibroblast growth factor in gastric tissues of ulcerated rats.

Beta-glucan H6PC20 (Mw: 2390 kDa) and α-heteropolysaccharide HPB-3 (Mw: 15 kDa) were purified from Hericium erinaceus, and their gastroprotective effects against ethanol-induced gastric ulcer in rats were confirmed, with the mechanism involving both increasing defense factors (EGF, bFGF, and PGE2) and down-regulating expression of inflammatory cytokines (IL-1β and TNF-α).

In human studies, H. erinaceus increased gut microbiota diversity and the abundance of short-chain fatty acid (SCFA)-producing bacteria, thereby reducing inflammation and protecting gut health. The majority of gastric evidence remains preclinical (animal and cell-culture models); robust human clinical trials in this area are limited.

5.5 Anticancer Activity

In vitro laboratory studies on cancer and cell apoptosis, focusing on leukemia and gastric cancer cells, found that isolated erinacine A from the mycelium of H. erinaceus inhibited the invasiveness of MKN28 and TSGH 9201 cells and activated caspase pathways. Mushroom extracts can inhibit the proliferation of various cancer cell types, including liver cancer (HepG2 and Huh-7), colon cancer (HT-29), and gastric cancer cell lines. All cancer-related evidence currently exists at the in vitro level; there are no published human clinical trials establishing anticancer efficacy.

5.6 Immune Function

Antioxidative, anti-inflammatory, anticancer, immunostimulant, antidiabetic, antimicrobial, hypolipidemic, and antihyperglycemic properties of H. erinaceus have been reported. Immune-modulating activity in human clinical settings has not been established in rigorous trials; most immunological data derive from in vitro and animal studies.

6. Body Systems Associated with Hericium erinaceus

• Central Nervous System: Hericium erinaceus is a valuable mushroom known for its strong bioactive properties, showing promising potential as a neuroprotective agent capable of stimulating nerve growth factor release, regulating inflammatory processes, reducing oxidative stress, and safeguarding nerve cells from apoptosis. The active compounds, such as erinacines and hericenones, have been the subject of research providing evidence of their neuroprotective effects.
• Gastrointestinal System: H. erinaceus has shown various anti-inflammatory, antioxidative, and gastroprotective properties, with relevance to gastric ulceration, chronic gastritis, and gut microbiota composition.
• Immune System: Extensive research has highlighted the pharmacological properties of its constituents, including neuroprotective, neurotrophic, immunomodulatory, and anticancer activities.
• Metabolic System: It has functions including enhancing immunity, antitumor effects, antioxidation, antihyperglycemic, antihyperlipidemic properties, and protecting gastric mucosa.

7. Dosage Forms and Doses Reported in Studies

In the pivotal 2008 Japanese MCI trial, the Yamabushitake group took four 250 mg tablets containing 96% of Yamabushitake dry powder three times a day (i.e., 3 g/day of dried powder) for 16 weeks.

One study used 1 g three times per day of powdered lion's mane fruiting bodies. Another used 3.2 g of powdered lion's mane fruiting bodies per day.

An acute crossover study administered a single dose of H. erinaceus fruiting body extract at 3 g of a 10:1 extract.

In the 2019 Vigna et al. study on mood disorders, participants were supplemented with a 500 mg capsule using an 80:20 mycelium to fruiting body ratio, with each individual ingesting 84 grams of H. erinaceus over an eight-week period.

A study on patients with depression, anxiety, and sleep disorder administered capsules containing H. erinaceus extract at 1,200 mg/capsule, 3 capsules/day for 8 weeks.

In a preclinical 28-day oral toxicology study in Sprague-Dawley rats, three doses of 1 (low), 2 (mid), and 3 (high) g/kg body weight/day were selected.

Long-term studies with standardized treatments are needed to fully understand the safety of lion's mane supplementation. Drug interactions are not known.

8. Safety Considerations

General Tolerability

Although commonly unreported, potential side effects of H. erinaceus include stomach discomfort, headache, and allergic reactions. Hericium erinaceus is possibly safe when taken by mouth as a medicine short-term; it has been used safely in people for up to 16 weeks. Side effects are mild and may include stomach discomfort.

Preclinical Toxicology

In a 28-day repeated oral administration toxicology study in Sprague-Dawley rats, all animals survived to the end of the study. No abnormal changes were observed in clinical signs. No adverse or test article-related differences were found in urinalysis, hematology, and serum biochemistry parameters between the treatment and control groups. No gross pathological findings and histopathological differences were seen. The no-observed-adverse-effect level (NOAEL) of erinacine A-enriched H. erinaceus was determined to be greater than 3 g/kg body weight/day.

Adverse Events in Clinical Trials

One trial reported that erinacine A-enriched H. erinaceus mycelia were "safe and well-tolerated"; however, four participants dropped out due to abdominal discomfort, nausea, and skin rash, and no other adverse events were reported among the remaining participants.

Blood Sugar and Anticoagulant Interactions

Hericium erinaceus might slow blood clotting, which could increase the chances of bruising and bleeding in people with bleeding conditions; however, there are no reports of this occurring in humans. Hericium erinaceus might also lower blood sugar; individuals with diabetes who use it should watch for signs of hypoglycemia and monitor blood sugar carefully.

Allergy

Allergic reactions, including contact dermatitis and respiratory symptoms, have been documented in case reports associated with H. erinaceus. Allergic reactions are listed as a potential side effect, though they are commonly unreported in the systematic literature.

Pregnancy and Lactation

Not enough is known about the use of Hericium erinaceus in medicinal amounts during pregnancy and breast-feeding.

Limitations of the Current Safety Evidence Base

Long-term studies with standardized treatments are needed to fully understand the safety of lion's mane supplementation. Further research and standardization processes for dietary supplements focused on H. erinaceus are essential to ensure effectiveness and safety in protecting the nervous system.

References

• Mori K. et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research. PubMed PMID: 18844328.
• Neurotrophic and Neuroprotective Effects of Hericium erinaceus. MDPI International Journal of Molecular Sciences, 2023. PMC10650066.
• Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines. PMC5987239.
• Acute effects of a standardised extract of Hericium erinaceus on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in Nutrition, 2025. PMC12018234.
• Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity. PMC6500611.
• Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases. World Journal of Gastroenterology, 2023. PMC10280799.
• Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond. PMC10218917.
• Lion's Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential — A Narrative Review. PMC12030463.
• Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. PubMed PMID: 40959699.
• Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. PMC12434001.
• Hericium erinaceus cultivated under tropical conditions: isolation of hericenones and demonstration of NGF-mediated neurite outgrowth in PC12 cells. PubMed PMID: 25288148.
• Chemical Constituents from Hericium erinaceus Promote Neuronal Survival and Potentiate Neurite Outgrowth via the TrkA/Erk1/2 Pathway. PMC5578049.
• Chemical constituents from Hericium erinaceus and their ability to stimulate NGF-mediated neurite outgrowth on PC12 cells. PubMed PMID: 26481911.
• Beyond Neurotrophins: A Proposed Neurotrophic-Epigenetic Axis for Hericium erinaceus Bioactives — A Hypothesis-Driven Review. PubMed PMID: 41683696.
• Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models. Frontiers in Pharmacology, 2025.
• Ma B.-J. et al. (2010). Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus. Mycology: An International Journal on Fungal Biology.
• Effect of erinacine A-enriched Hericium erinaceus supplementation on cognition: A randomized, double-blind, placebo-controlled pilot study. ScienceDirect, 2024.
• Hericium erinaceus: A possible future therapeutic treatment for the prevention and delayed progression of Alzheimer's disease? Nutrition Research Reviews, Cambridge Core.
• Therapeutic Potential of Hericium erinaceus for Depressive Disorder. International Journal of Molecular Sciences, 2020. MDPI.
• The ethnopharmacology, phytochemistry and pharmacology of the genus Hericium. Journal of Ethnopharmacology, 2023. ScienceDirect.
• Rapid Identification of Chemical Constituents in Hericium erinaceus Based on LC-MS/MS Metabolomics. Journal of Food Quality, 2021.
• Hericenones From Hericium erinaceus: A Scoping Review of Structural Diversity and Health Benefits. Chemistry & Biodiversity, 2026.
• Gastroprotective activity of polysaccharide from the fruiting body of Hericium erinaceus against acetic acid-induced gastric ulcer in rats. International Journal of Biological Macromolecules, 2022.
• Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. PubMed PMID: 24810469.
• Alzheimer's Drug Discovery Foundation (ADDF): Cognitive Vitality Report — Lion's Mane (Hericium erinaceus).
• Hericium erinaceus. Wikipedia (citing primary sources).